Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Details Textual)

v3.5.0.2
Intangible Assets (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 4 Months Ended 9 Months Ended
May 02, 2016
Jul. 31, 2016
Sep. 30, 2015
May 02, 2016
Sep. 30, 2016
Sep. 30, 2015
May 31, 2016
Indefinite-lived Intangible Assets [Line Items]              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities             $ 1,000,000
Stock Issued During Period, Shares, New Issues       234,296      
Houston Pharmaceuticals, Inc [Member]              
Indefinite-lived Intangible Assets [Line Items]              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities         $ 3,874,000    
Stock Issued During Period, Shares, New Issues   629,000          
Accrued license agreement payment   $ 100,000          
Share Price   $ 6.00          
Moleculin LLC [Member]              
Indefinite-lived Intangible Assets [Line Items]              
Notes Receivable, Related Parties $ 57,822     $ 57,822      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities         1,205,564    
Royalty On Net Revenues 2.50%     2.50%      
Share Price $ 6.00     $ 6.00      
Moleculin LLC [Member] | Acquisition Date One [Member]              
Indefinite-lived Intangible Assets [Line Items]              
Amortization of Debt Issuance Costs and Discounts         $ 145,078    
Moleculin LLC [Member] | Acquisition Date Two [Member]              
Indefinite-lived Intangible Assets [Line Items]              
Amortization of Debt Issuance Costs and Discounts     $ 112,846        
Moleculin LLC [Member] | Acquisition Date Three [Member]              
Indefinite-lived Intangible Assets [Line Items]              
Amortization of Debt Issuance Costs and Discounts           $ 322,547  
Moleculin LLC [Member] | License Agreement [Member] | Houston Pharmaceuticals, Inc [Member]              
Indefinite-lived Intangible Assets [Line Items]              
Stock Issued During Period, Shares, New Issues 629,000            
Accrued license agreement payment $ 100,000     $ 100,000      
Moleculin LLC [Member] | Out-Lincense Agreement [Member] | Houston Pharmaceuticals, Inc [Member]              
Indefinite-lived Intangible Assets [Line Items]              
Licencing Arrangements Consideration Payable 750,000     750,000      
Licencing Arrangements Reserve 1,000,000     1,000,000      
Payments to Acquire Intangible Assets $ 1,000,000            
Common Stock [Member] | Moleculin LLC [Member]              
Indefinite-lived Intangible Assets [Line Items]              
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 999,931            
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned $ 5,999,586     $ 5,999,586